[Carbohydrates and vaccines: from purified polysaccharides to semi-synthetic glycoconjugate vaccines].
Over the last decades, capsular polysaccharides have been successfully used as antibacterial vaccines. Marketing several polysaccharide-protein conjugate vaccines filled the gap in many areas of children and infant vaccination. By facilitating access to structures of increasing complexity, recent progress in glycochemistry has enabled the design of more and more precisely defined glycoconjugate vaccines using synthetic saccharide components which mimic epitopes naturally implicated in protection. This strategy was recently validated in humans. It opens the way to new perspectives in vaccine research devoted to prophylactic and/or therapeutic applications against bacterial, fungal, parasitic or viral infections, and certain cancers.
Mulard
L
L
Unité de Chimie Organique, Ura Cnrs 2128, Institut Pasteur, 28, rue du Dr Roux F 75724 Paris Cedex 15. lmulard@pasteur.fr
D000818:Animals; D000941:Antigens / Q000737:chemistry / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D005657:Fungal Vaccines / Q000276:immunology / Q000627:therapeutic use; D006001:Glycoconjugates / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D010272:Parasitic Diseases / Q000276:immunology / Q000517:prevention & control; D011134:Polysaccharides / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use; D018074:Vaccines, Conjugate / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use; D014765:Viral Vaccines / Q000276:immunology / Q000627:therapeutic use
D000941:Antigens; D001428:Bacterial Vaccines; D019496:Cancer Vaccines; D005657:Fungal Vaccines; D006001:Glycoconjugates; D011134:Polysaccharides; D018074:Vaccines, Conjugate; D014765:Viral Vaccines